Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival

Richard Kelly(Nottingham City Council), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Walter M. Gregory(University of Leeds), Lindsay Mitchell(Monklands Hospital), Stephen J. Richards(St James's University Hospital), D. Cohen(University of Leeds), Louise Arnold(Leeds Teaching Hospitals NHS Trust), Gemma L Brooksbank(Leeds Teaching Hospitals NHS Trust), Matthew Cullen(Leeds Teaching Hospitals NHS Trust), Anita Hill(Leeds Teaching Hospitals NHS Trust)
Blood
April 2, 2011
10.1182/blood-2011-02-333997
Cited by 514

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k